FDA Grants Approval to Taletrectinib for Advanced ROS1+ NSCLC

The FDA approved a supplemental new drug application (sNDA) for taletrectinib (Ibtrozi; Nuvation Bio Inc.) for advanced ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC). This action updates the drug’s label with longer-term efficacy data in patients who are tyrosine kinase inhibitor (TKI)-naïve. The updated data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 and simultaneously published in the Journal of Clinical Oncology.^1,2

What is Taletrectinib?

Taletrectinib originally received full FDA approval on June 11, 2025, following priority review and breakthrough therapy designations for adult patients with locally advanced or metastatic ROS1+ NSCLC across lines of therapy. The indication extended to those who were TKI-naïve and had TKI-pretreated disease.¹

Taletrectinib’s approval was supported by the TRUST clinical program, which consists of 3 registrational trials: the phase 2 TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials, which evaluated taletrectinib in advanced ROS1+ NSCLC and helped support the drug’s approval; and the phase 3 TRUST-IV (NCT07154706) trial, a placebo-controlled study that evaluated taletrectinib as adjuvant therapy in resected early-stage ROS1+ NSCLC. Additionally, the program will also include TRUST-III (NCT06564324), a confirmatory randomized phase 3 study evaluating taletrectinib versus crizotinib (Xalkori; Pfizer) in patients with advanced ROS1+ NSCLC who were not previously treated with ROS1 TKIs.¹

What Trial Data Supported the Approval?

The sNDA approval is based on a median follow-up of about 51 months for patients in TRUST-I, a multicenter, single-arm, open-label study. Additionally, it incorporates an additional 14 months of data from both the TRUST-I and TRUST-II studies, as of an August 2025 data cutoff. With longer follow-up, taletrectinib continued to demonstrate high and durable response rates in both TKI-naïve and crizotinib-pretreated patients, including intracranial activity and promising overall survival (OS).^2,3

Specifically, among 103 TKI-naïve patients who started taletrectinib at 600 mg once per day (median follow-up: 51.0 months), the objective response rate (ORR) was approximately 90.3% (95% CI, 82.9-95.3), the median duration of response (DOR) 49.7 months, and the median progression-free survival (PFS) 49.6 months. Of note, the median OS was not reached.²

Among 66 crizotinib-pretreated patients (median follow-up: 45.2 months), the ORR was approximately 51.5%, the median DOR was 13.2 months, the median PFS was 7.6 months, and the median OS was 25.6 months. The safety profile remained consistent with prior reports, and no new safety signals were identified.²

Safety Profile

The most frequently reported adverse events (AEs) occurring in at least 20% of patients were diarrhea, nausea, vomiting, dizziness, rash, constipation, and fatigue. The label continues to carry warnings for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity.^1,2

ROS1+ disease accounts for approximately 2% of NSCLC diagnoses each year, a population in which about 35% of patients newly diagnosed with metastatic disease already have brain metastases, and roughly half of previously treated patients will develop central nervous system (CNS) involvement. Taletrectinib is designed as a CNS-active, next-generation ROS1 inhibitor intended to address that unmet need.

For pharmacists, the extended DOR and PFS data reinforce taletrectinib’s positioning as a durable first-line option in ROS1+ NSCLC and may factor into discussions around treatment sequencing, monitoring expectations, and patient counseling on long-term therapy adherence.

“This approval is a significant milestone for [taletrectinib] because this data is now part of the FDA-approved label, something physicians and patients can turn to directly,” David Hung, MD, founder, president, and CEO of Nuvation Bio said in a news release. “A median DOR of more than 4 years—the longest median DOR reported for an FDA-approved ROS1 TKI—is a remarkable outcome for people living with ROS1+ NSCLC, and having it in the label means something real for patients: a clearer sense of how long they might expect to stay on treatment and more confidence in what that path could look like at a moment when a new diagnosis can feel overwhelming. It also gives physicians additional evidence to support using IBTROZI early in a patient's care, when that choice matters most.”¹

REFERENCES

1. Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer. Nuvation Bio. News release. September 17, 2026. Accessed September 17, 2026. https://investors.nuvationbio.com/news/news-details/2026/Nuvation-Bio-Announces-FDA-Approval-of-Supplemental-New-Drug-Application-for-IBTROZI-taletrectinib-with-Updated-Duration-of-Response-in-TKI-Nave-Advanced-ROS1-Positive-Non-Small-Cell-Lung-Cancer/default.aspx

2. Li W, Zhang Y, Fan H, et al. long-term efficacy and safety of taletrectinib in patients with ros1+ non–small cell lung cancer: Results from the phase II TRUST-I study. J Clin Oncol. 2026;44(18):1670-1675. doi:10.1200/JCO-26-00434

3. A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene. ClinicalTrials.gov identifier: NCT04395677. Updated February 6, 2026. Accessed September 17, 2026. https://clinicaltrials.gov/study/NCT04395677